The court found that the university had failed to demonstrate that one of its researchers had collaborated with the IP's inventors and therefore is not entitled to co-inventorship.
The firm also said it aims to soon begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria type 1.
The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
The proceeds will be used to advance its drug candidates and for general corporate purposes.
The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.
Advances in human genetics and siRNA delivery have helped drive the programs, according to company officials.
Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.
The therapy is the company's first to feature an optimized version of its GalNAc conjugate delivery technology.
The trial will include both healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria.
The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.